{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+%28agonist%29",
    "query": {
      "intervention": "GnRH (agonist)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 182,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+%28agonist%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T23:09:43.474Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07717866",
      "title": "Trifecta Research Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PTSD - Post Traumatic Stress Disorder",
        "Cognitive Dysfunction",
        "Brain Injury",
        "Depression - Major Depressive Disorder",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "Magnetic e-Resonance Therapy (MeRT)",
          "type": "DEVICE"
        },
        {
          "name": "Ibogaine Hydrochloride with Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "5-methoxy-N,N-dimethyltryptamine",
          "type": "DRUG"
        },
        {
          "name": "Physiological Supplementation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Axial Therapeutic Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-08-01",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1,
      "location_summary": "Northridge, California",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07717866"
    },
    {
      "nct_id": "NCT01546987",
      "title": "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH agonist",
          "type": "DRUG"
        },
        {
          "name": "Anti-androgen",
          "type": "DRUG"
        },
        {
          "name": "TAK-700",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 239,
      "start_date": "2012-05",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 165,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01546987"
    },
    {
      "nct_id": "NCT00458458",
      "title": "Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis",
        "Dysmenorrhea",
        "Dyspareunia"
      ],
      "interventions": [
        {
          "name": "Norethindrone Acetate (NA)",
          "type": "DRUG"
        },
        {
          "name": "GnRH Agonist (Lupron Depot)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 112,
      "start_date": "2004-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458458"
    },
    {
      "nct_id": "NCT04482374",
      "title": "Puberty Suppression and Cardiometabolic Health",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transgenderism",
        "Insulin Sensitivity/Resistance",
        "Endothelial Dysfunction",
        "Vascular Stiffness"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "14 Years",
        "sex": "MALE",
        "summary": "9 Years to 14 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-10",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482374"
    },
    {
      "nct_id": "NCT00005044",
      "title": "Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Casodex",
          "type": "DRUG"
        },
        {
          "name": "Eulexin",
          "type": "DRUG"
        },
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 1579,
      "start_date": "2000-02",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 241,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005044"
    },
    {
      "nct_id": "NCT05879926",
      "title": "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ovarian Function Suppression + Aromatase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant Chemotherapy + Ovarian Function Suppression",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 3960,
      "start_date": "2023-10-18",
      "completion_date": "2034-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1226,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05879926"
    },
    {
      "nct_id": "NCT06922318",
      "title": "The COSMYC Trial (COmbined Suppression of MYC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) analogue",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-19",
      "completion_date": "2031-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06922318"
    },
    {
      "nct_id": "NCT03047330",
      "title": "Menopausal Sleep Fragmentation and Body Fat Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menopause"
      ],
      "interventions": [
        {
          "name": "Estradiol withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Fragmented sleep",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2017-07-15",
      "completion_date": "2022-08-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03047330"
    },
    {
      "nct_id": "NCT01492972",
      "title": "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Androgen Suppression Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Proton Collaborative Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 192,
      "start_date": "2012-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Hampton",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492972"
    },
    {
      "nct_id": "NCT05422911",
      "title": "Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Neoplasm, Prostate",
        "Castrate-sensitive",
        "Castrate-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 192,
      "start_date": "2022-08-31",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-23T23:09:43.474Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422911"
    }
  ]
}